Literature DB >> 19698830

The Norwood procedure using a right ventricle-pulmonary artery conduit: comparison of the right-sided versus left-sided conduit position.

David J Barron1, Andre Brooks, John Stickley, Steven M Woolley, Oliver Stümper, Timothy J Jones, William J Brawn.   

Abstract

OBJECTIVE: We proposed that a right-sided right ventricle-pulmonary artery conduit during the stage I Norwood procedure would facilitate pulmonary artery reconstruction during the stage II procedure.
METHODS: Between 2002 and 2006, 153 patients underwent Norwood stage I reconstruction with a right ventricle-pulmonary artery conduit (125 in the right-sided group and 28 in the left-sided group). The previous 150 consecutive classic Norwood procedures (1997-2002) were used as a control group. Outcomes from stages I and II were analyzed, including ventricular function and pulmonary artery morphology.
RESULTS: The 30-day survival was 88% (110/125) in the right-sided group, 75% (21/28) in the left-sided group, and 70% (105/150) in the control group (P < .001, right-sided vs control groups). The conduit length was 35 +/- 9 mm in the right-sided group and 26 +/- 8 mm in the left-sided group (P = .001). Survival at 6 months demonstrated a significant survival benefit in the right-sided right ventricle-pulmonary artery conduit group over the control group (P = .009, log-rank test). There was no difference in ventricular function between the groups and no regional dyskinesia associated with the right ventricle-pulmonary artery conduit. Despite larger branch pulmonary artery size in the right ventricle-pulmonary artery conduit groups (compared with the control group), central pulmonary artery stenoses were common (62% in the right conduit and 80% in the left conduit). Bypass and ischemic times at stage II were 49 +/- 10 and 23 +/- 13 minutes in the right-sided group compared with 61.5 +/- 9.5 and 31 +/- 14 minutes in the left-sided group (P < .001 and P = .03, respectively). The 30-day mortality after the stage II procedure was 1.3% (1/76) in the right-sided group, 0% (0/18) in the left-sided group, and 3.3% (3/90) in the control group.
CONCLUSION: The right-sided conduit is a safe technique and has improved 30-day and overall post-stage II survival compared with that seen with the classic Norwood procedure. The right ventricle-pulmonary artery conduit is associated with central pulmonary artery stenosis but good development of the branch pulmonary arteries and preservation of ventricular function. The right-sided conduit significantly reduces cardiopulmonary bypass times at stage II.

Entities:  

Mesh:

Year:  2009        PMID: 19698830     DOI: 10.1016/j.jtcvs.2009.05.004

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Fate of ventricular and valve performance following early bidirectional Glenn procedure after Norwood operation controlled for hypoplastic left heart syndome anatomic subtype.

Authors:  Anastasios C Polimenakos; John W Bokowski; Hani S Ghawi; Chawki F El-Zein; Michel N Ilbawi
Journal:  Pediatr Cardiol       Date:  2013-10-15       Impact factor: 1.655

2.  An angiographic predictor of pulmonary artery stenosis after the Norwood-Sano operation for hypoplastic left heart syndrome.

Authors:  Michael D Seckeler; Carlos M Mery; James J Gangemi; Benjamin B Peeler; K Anitha Jayakumar
Journal:  Pediatr Cardiol       Date:  2012-03-24       Impact factor: 1.655

3.  Hypoplastic left heart syndrome and aortic atresia-mitral stenosis variant: role of myocardial protection strategy and impact of ventriculo-coronary connections after stage I palliation.

Authors:  Anastasios C Polimenakos; Shyam K Sathanandam; Tarek S Husayni; Chawki F El Zein; David A Roberson; Michel N Ilbawi
Journal:  Pediatr Cardiol       Date:  2011-06-05       Impact factor: 1.655

4.  Hypoplastic left heart syndrome: current modalities of treatment and outcomes.

Authors:  Smruti Ranjan Mohanty; Agastya Patel; Simran Kundan; Hari Bipin Radhakrishnan; Suresh Gururaja Rao
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.